JGC Holdings Corp. has invested in Alpha Fusion Inc., a start-up developing innovative anti-cancer drugs through Targeted Alpha Therapy, positioning itself in the expanding Japanese healthcare market.

Information on the Target

Alpha Fusion Inc. is a start-up founded in April 2021, headquartered in Osaka, Japan. The company specializes in developing anti-cancer drugs using Targeted Alpha Therapy (TAT) that employs astatine (At-211) to treat hard-to-treat cancers. TAT is distinguished from conventional beta and gamma treatments due to its precision, safety, and powerful ability to kill cancer cells.

The use of TAT represents a significant breakthrough in oncology, combining nuclear physics, drug chemistry, and medical biology to achieve what is often regarded as "micro-surgery" for tumors. By linking alpha-emitting isotopes with compounds that specifically bind to cancer tumors, TAT aims to selectively target and destroy cancer cells, offering unprecedented efficacy and safety.

Industry Overview in Japan

Japan’s healthcare and life sciences industry has seen substantial advancements, particularly in biopharmaceuticals and cancer treatment technologies. The increasing prevalence of cancer has spurred demand for innovative therapies